Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-dose versus standard-dose eptifibatide in acute coronary syndrome
IRCT20230805059045N1Phase 2Completed
- Sponsor
- Guilan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label trial of eptifibatide in acute coronary syndrome (ACS) (2 arms), sponsored by Guilan University of Medical Sciences. Primary endpoints: Percentage of left ventricular ejection fraction improvement, Minor bleeding and 8 more. Started Aug 2023; status: completed.
02
Drugs
eptifibatide
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on IRCT20230805059045N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230805059045N1.